<div class="container">

<table style="width: 100%;"><tr>
<td>persistency_data</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>Drug persistency (retention) rates by different therapeutic class.</h2>

<h3>Description</h3>

<p>A dataset containing drug persistency of patients in different therapeutic classes.
</p>


<h3>Usage</h3>

<pre><code class="language-R">data(persistency_data)
</code></pre>


<h3>Format</h3>

<p>A data frame 334 observatios and 3 variables:
</p>

<dl>
<dt>therapy</dt>
<dd>
<p>Type of therapy. Unique values include: <code>"Hypertension" "Occular Hypertension"
  "Statin" "Insulin" "Epilepsy" "RA" "Osteoporosis" "Alzheimer""ADHD"
  "Atrial Fibrillation"</code>. See references below.
Data was extracted using <a href="https://automeris.io/WebPlotDigitizer/">https://automeris.io/WebPlotDigitizer/</a>
and discretized using <code>akima</code> package.</p>
</dd>
<dt>time_period</dt>
<dd>
<p>Time Period</p>
</dd>
<dt>value</dt>
<dd>
<p>% Patients retained</p>
</dd>
</dl>
<h3>References</h3>

<p><code>Hypertension:</code> Solomon M, Goldman D, Joyce G, Escarce J. Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill.Archives of Internal Medicine. 2009;169(8):740-748.
</p>
<p><code>Occular Hypertension:</code> Campbell J, Schwartz G, LaBounty B, Kowalski J, Patel. Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. Clinical Ophthalmology. 2014;8:927-935.
</p>
<p><code>Statin:</code> Kiss Z, Nagy L, Reiber I, Paragh G, Molnar M, Rokszin G et al. Persistence with statin therapy in Hungary. Archives of Medical Science. 2013;9(3):409-417.
</p>
<p><code>Insulin:</code> Roussel R, Charbonnel B, Behar M, Gourmelen J, Emery C, Detournay B. Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study. Diabetes Therapy. 2016;7(3):537-549.
</p>
<p><code>Epilepsy:</code> Lai E, Hsieh C, Su C, Yang Y, Huang C, Lin S et al. Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study. Medicine. 2016;95(35):e4481.
</p>
<p><code>RA:</code> Neovius M, Arkema E, Olsson H, Eriksson J, Kristensen L, Simard J et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Annals of the Rheumatic Diseases. 2013;74(2):354-360.
</p>
<p><code>Osteoporosis:</code> Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Archives of Osteoporosis. 2015;10(27):1-6. 
</p>
<p><code>Alzheimer:</code>  Suh D, Thomas S, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs &amp; Aging. 2005;22(8):695-707.
</p>
<p><code>ADHD:</code> Beau-Lejdstrom R, Douglas I, Evans S, Smeeth L. Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open. 2016;6(6):1-8.
</p>
<p><code>Atrial Fibrillation:</code> Gomes T, Mamdani M, Holbrook A, Paterson J, Juurlink D. Persistence With Therapy Among Patients Treated With Warfarin for Atrial Fibrillation. Archives of Internal Medicine. 2012;172(21):1687-1689.
</p>


</div>